BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/480/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 08:22:11 17/05/2024 pm IST | ||
| 2.41 EUR | +2.99% |
|
| Current month | +110.81% | ||
| 1 month | +58.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 2.41 | +2.99% |
| 16/24/16 | 2.34 | +3.08% |
| 15/24/15 | 2.27 | +19.47% |
| 14/24/14 | 1.9 | -5.47% |
| 13/24/13 | 2.01 | +11.67% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 08:22 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VD3R79 |
| ISIN | DE000VD3R793 |
| Date issued | 09/04/2024 |
| Strike | 480 $ |
| Maturity | 20/12/2024 (217 Days) |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.41 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.04 € |
| Spread % | 1.54% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Warrants
- Warrant
